Immix Biopharma (IMMX) Other Non-Current Liabilities (2020 - 2021)
Immix Biopharma's (IMMX) quarterly Other Non-Current Liabilities came in at $23.4 million in Q4 2021, up 3972.14% year-on-year from $575000.0 in Q4 2020, and up 3972.14% quarter-over-quarter from $575000.0 in Q4 2020.
Immix Biopharma (IMMX) Other Non-Current Liabilities (2020 - 2021) Analysis & Trends
Immix Biopharma has disclosed Other Non-Current Liabilities across 2 years of filings, most recently posting $23.4 million for Q4 2021.
- Other Non-Current Liabilities for Q4 2021 came in at $23.4 million, up 3972.14% year-over-year; the trailing twelve-month figure through Dec 2021 was $23.4 million (up 3972.14% YoY), and the FY2021 annual result was $23.4 million, up 3972.14% from the prior year.
- Other Non-Current Liabilities came in at $23.4 million for Q4 2021 at Immix Biopharma, up from $575000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $23.4 million in Q4 2021 to a low of $575000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Immix Biopharma | 467.59 Mn | 467.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 23.41 Mn |
| Dec 31, 2020 | 575,000.00 |